Allogene Therapeutics reported a first-quarter 2026 net loss of $42.6 million, or $0.18 per share, on a quarter that included the planned interim futility analysis of its lead asset cema-cel, and closed a $200.4 million underwritten public offering six weeks later that reset the balance sheet to a runway extending into the first quarter of 2029. The interim futility analysis, reported in April 2026, cleared the protocol-defined bar with a 41.6 percentage-point absolute difference in minimal residual disease (MRD) clearance between cema-cel and observation in the first 24 randomized patients of the pivotal Phase 2 ALPHA3 trial, a separation Allogene characterizes as supportive of cema-cel's potential as an outpatient, MRD-guided consolidation therapy in first-line large B-cell lymphoma (LBCL). With the equity raise executed, the next 18 months of clinical execution are funded through the interim event-free survival (EFS) readout in mid-2027 and a BLA submission if the primary EFS analysis in mid-2028 reads positive.
The single load-bearing risk is whether cema-cel's early MRD-clearance advantage translates into a statistically and clinically meaningful EFS benefit at the interim analysis in mid-2027, because MRD clearance is a biomarker (a measurable biological signal that correlates with disease status) and is not a regulatory endpoint on its own. The trial is powered to detect a 50% reduction in EFS events across approximately 220 patients, with enrollment expected to complete by the end of 2027 and a primary EFS readout in mid-2028. The falsifiable clock is the next 10-Q (for the second quarter of 2026), which carries the second-quarter net loss and the post-offering cash position; interim ALPHA3 enrollment updates; and the next ALLO-329 update, scheduled for the fourth quarter of 2026.